Thrombotic complications in patients with liver cirrosis: current state of the problem


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The purpose of this review was to provide an update on the epidemiology, risk factors, and treatment of thrombotic complications in patients with cirrhosis. It has been shown that liver cirrhosis significantly increases the risk of various thrombotic complications and cardiomyopathy associated with the development of atrial fibrillation. On the other hand, thrombosis of the visceral veins: portal vein thrombosis, splenic and superior mesenteric veins cause CP decompensation. There is evidence that the use of anticoagulant therapy in patients with atrial fibrillation and liver cirrhosis increases the overall mortality of such patients, compared with those who do not receive such therapy. All this leads to significant difficulties in the treatment of patients. Currently, it is proved that anticoagulant therapy in patients with thrombosis of internal organs against the background of liver cirrhosis should be carried out for at least 6 months, and in case of relapses, for life. At the same time, the choice of anticoagulant therapy among patients with liver cirrhosis is not always unambiguous, which requires further investigation of the existing problem.

Full Text

Restricted Access

About the authors

Alexey M. Osadchuk

Russian Medical Academy of Continuing Professional Education of the Ministry of Healthcare of Russia

Email: a.m.osadchuk2020@mail.ru
MD, professor, professor of the Department of gastroenterology

Maxim M. Osadchuk

Medical University «Reaviz»

PhD, associate professor, associate professor of the Department of clinical medicine

Irina A. Zolotovskaya

Samara State Medical University of the Ministry of Healthcare of Russia

Email: zolotovskay@list.ru
MD, professor of the Department of hospital therapy with courses of polyclinic therapy and transfusiology

References

  1. Ponziani F.R., Zocco M.A., Garcovich M. et al. What we should know about portal vein thrombosis in cirrhotic patients: A changing perspective. World J. Gastroenterol. 2012; 18(36): 5014-20. doi: 10.3748/wjg.v18.i36.5014.
  2. Ивашкин В.Т., Маевская М.В., Павлов Ч.С. с соавт. Клинические рекомендации Российского общества по изучению печени и Российской гастроэнтерологической ассоциации по лечению осложнений цирроза печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016; 4: 71-102. doi: https://dx.doi.org/10.22416/1382-4376-2016-26-4-71-102.
  3. Anstee Q.M., Mantovani A., Tilg H., Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2018; 15(7): 425-39. doi: 10.1038/s41575-018-0010-0.
  4. Chokesuwattanaskul R., Thongprayoon C., Bathini T. et al. Epidemiology of atrial fibrillation in patients with cirrhosis and clinical significance: a meta-analysis. Eur J. Gastroenterol Hepatol. 2019; 31(4): 514-19. doi: 10.1097/MEG.0000000000001315.
  5. Itani W., Nassar Y., Richter S., Torosoff M. Atrial fibrillation and liver cirrhosis: risks and benefits of anticoagulation. J. Am Coll Cardiol. 2019; 73(9 Suppl 1): 395. doi: 10.1016/S0735-1097(19)31003-4.
  6. Aggarwal A., Puri K., Liangpunsakul S. Deep vein thrombosis and pulmonary embolism in cirrhotic patients: Systematic review. World J. Gastroenterol. 2014; 20(19): 5737-45. doi: 10.3748/wjg.v20.i19.5737.
  7. Northup P.G., McMahon M.M., Ruhl A.P. et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J. Gastroenterol. 2006; 101(7): 1524-28; quiz 1680. doi: 10.1111/j.1572-0241.2006.00588.x.
  8. Wu H., Nguyen G.C. Liver cirrhosis is associated with venous thromboembolism among hospitalized patients in a nationwide US study. Clin Gastroenterol Hepatol. 2010; 8(9): 800-05. doi: 10.1016/j.cgh.2010.05.014.
  9. Intagliata N.M., Argo C.K., Stine J.G. et al. Concepts and controversies in haemostasis and thrombosis associated with liver disease: Proceedings of the 7th International Coagulation in Liver Disease Conference. Thromb Haemost. 2018; 118(8): 1491-506. doi: 10.1055/s-0038-1666861.
  10. Garcia-Villa A., Yarza R., Pages M. et al. Cancer-associated splanchnic venous thrombosis: clinical findings at presentation. 9th International Conference on Thrombosis and Hemostasis Issues in Cancer. ICTHIC; 2018. Italy.
  11. Kearon C. Natural history of venous thromboembolism. Circulation. 2003; 107(23 Suppl 1): I22-30. doi: 10.1161/01. CIR.0000078464.82671.78.
  12. Ambrosino P., Tarantino L., Di Minno G. et al. The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis. Thromb Haemost. 2017; 117(1): 139-48. doi: 10.1160/TH16-06-0450.
  13. Villa E., Camma C., Marietta M. et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012; 143(5): 1253-60.e4. doi: 10.1053/j.gastro.2012.07.018.
  14. Valeriani E., Riva N., Di Nisio M., Ageno W. Splanchnic vein thrombosis: Current perspectives. Vasc Health Risk Manag. 2019; 15: 449-61. doi: 10.2147/VHRM.S197732.
  15. Faccia M., Ainora M.E., Ponziani F.R. et al. Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate. World J. Gastroenterol. 2019; 25(31): 4437-51. doi: 10.3748/wjg.v25.i31.4437.
  16. Caldeira D., Barra M., Santos A.T. et al. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. Heart. 2014; 100(7): 550-56. doi: 10.1136/heartjnl-2013-305288.
  17. Levy J.H., Douketis J., Weitz J.I. Reversal agents for non-vitamin K. antagonist oral anticoagulants. Nat Rev Cardiol. 2018; 15(5): 273-81. doi: 10.1038/nrcardio.2017.223.
  18. Elhosseiny S., Moussawi H.A., Chalhoub J.M. et al. Direct oral anticoagulants in cirrhotic patients: Current evidence and clinical observations. Can J. Gastroenterol Hepatol. 2019; 2019: 4383269. doi: 10.1155/2019/4383269.
  19. Qamar A., Vaduganathan M., Greenberger N.J., Giugliano R.P. Oral anticoagulation in patients with liver disease. J. Am Coll Cardiol. 2018; 71(19): 2162-75. doi: 10.1016/j.jacc.2018.03.023.
  20. Ha N.B., Regal R.E. Anticoagulation in patients with cirrhosis: Caught between a rock-liver and a hard place. Ann Pharmacother. 2016; 50(5): 402-09. doi: 10.1177/1060028016631760.
  21. Intagliata N.M., Henry Z.H., Maitland H. et al. Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation. Dig Dis Sci. 2016; 61(6): 1721-27. doi: 10.1007/s10620-015-4012-2.
  22. Hum J., Shatzel J.J., Jou J.H. et al. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. Eur J. Haematol. 2017; 98(4): 393-97. doi: 10.1111/ejh.12844.
  23. Kuo L., Chao T.-F., Liu C.-J. et al. liver cirrhosis in patients with atrial fibrillation: Would oral anticoagulation have a net clinical benefit for stroke prevention? J. Am Heart Assoc. 2017; 6(6): e005307. doi: 10.1161/JAHA.116.005307.
  24. Bathini J.T., Chokesuwattanaskul R., Thongprayoon C., O'Corragain O.A. Anticoagulation for atrial fibrillation in patients with cirrhosis: a meta-analysis. J. Am Coll Cardiol. 2019; 73 (9 Suppl 1): 360. doi: 10.1016/S0735-1097(19)30968-4.
  25. Chokesuwattanaskul R., Thongprayoon C., Bathini T. et al. Efficacy and safety of anticoagulation for atrial fibrillation in patients with cirrhosis: A systematic review and meta-analysis. Dig Liver Dis. 2019; 51(4): 489-95. doi: 10.1016/j.dld.2018.12.001.
  26. Nakornchai W., Rojnuckarin P. Bleeding risk of warfarin therapy among cirrhotic patients. J. Hematol Transfus Med. 2019; 29: 205-13.
  27. Delgado M.G., Seijo S., Yepes I. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol. 2012; 10(7): 776-83. doi: 10.1016/j.cgh.2012.01.012.
  28. Kearon C., Akl E.A., Comerota A.J. et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141(2 Suppl): e419S-e496S. doi: 10.1378/chest.11-2301.
  29. European Association for the Study of the Liver. EASL clinical practice guidelines: vascular diseases of the liver. J. Hepatol. 2016; 64(1): 179-202. doi: 10.1016/j.jhep.2015.07.040.
  30. Huang W.A., Dunipace E.A., Sorg J.M., Vaseghi M. Liver disease as a predictor of new-onset atrial fibrillation. J. Am Heart Assoc. 2018; 7(15): e008703. doi: 10.1161/JAHA.118.008703.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies